GlucoTrack (NASDAQ:GCTK) Shares Down 7.5% – Time to Sell?

GlucoTrack, Inc. (NASDAQ:GCTK) shares fell 7.5% during mid-day trading on Monday . The company traded as low as $6.27 and last traded at $6.29. 9,069 shares changed hands during trading, a decline of 99% from the average session volume of 669,445 shares. The stock had previously closed at $6.80.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GlucoTrack in a research report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

GlucoTrack Trading Down 7.5%

The stock’s 50-day moving average price is $6.35 and its 200 day moving average price is $6.47. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.27 and a quick ratio of 3.27. The firm has a market capitalization of $5.73 million, a PE ratio of -0.18 and a beta of 0.24.

Institutional Trading of GlucoTrack

An institutional investor recently raised its position in GlucoTrack stock. Bank of America Corp DE boosted its holdings in shares of GlucoTrack, Inc. (NASDAQ:GCTK) by 102,125.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,089 shares of the company’s stock after acquiring an additional 4,085 shares during the period. Bank of America Corp DE owned about 0.85% of GlucoTrack worth $25,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 10.92% of the company’s stock.

GlucoTrack Company Profile

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.